ABPI responds to latest publication of Scorecard data on use of NICE-approved medicines across NHS in England

NewsGuard 100/100 Score

The figures, published today [Tuesday, 12 January] are from latest publication of the NICE Technology Appraisals in the NHS in England - Innovation Scorecard. Published by the Health and Social Care Information Centre (HSCIC), the Scorecard pulls together existing local data from across the NHS to show the regional provision of NICE-approved medicines and technologies.

ABPI’s acting CEO, Alison Clough, said:

We are not surprised to see that today’s figures show that access to modern medicines to treat and prevent a wide range of diseases, including cancer and diabetes, is still subject to wide variation across England. In some cases we are seeing variation of 30 fold in access to GP or hospital prescribed medicines - for example for newer stroke prevention medicines– all of which are approved by Nice as being clinically and cost effective and should therefore be widely and routinely available.

Without further detail and analysis of the figures it is difficult to know why we are seeing such wide variation in patient access to newer medicines. The ability to access potentially life-saving or life-enhancing medication shouldn’t be dependent solely on cost or geography and it would be disappointing if this was the case in some areas. The ABPI will be carrying out an immediate investigation into today’s figures and we will be working with the appropriate bodies – NHS, patient groups and charities – to try and address issues of inequality of access for those patients who, for whatever reason, are missing out on the most appropriate medicines for their care.

The ABPI is completely supportive of the Scorecard to measure the uptake of new medicines and drive innovation, but for the scheme to be a success we - and all of the organisations involved - must begin to address the reasons for the persistently low levels of medicines access that we believe the scorecard is highlighting and take action.

In order to achieve this the Scorecard needs to be more widely understood so that it can be used at local planning level by the NHS. For this to happen it is vital that the scorecard be launched in a more user friendly and easy to understand format.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals lifestyle factors boosting IVF success